Lingran Du
- Pharmaceutical Science top 5%
- Advancements in Transdermal Drug Delivery 2
- Advanced Drug Delivery Systems 2
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery 4
-
- RNA Interference and Gene Delivery 3
- Advanced biosensing and bioanalysis techniques 3
-
- Radiopharmaceutical Chemistry and Applications 2
-
- Hepatocellular Carcinoma Treatment and Prognosis 2
-
- Intracranial Aneurysms: Treatment and Complications 2
- Co-authors
- Jijun FuYi ZhouXiyong YuYugang HuangHe WangMinyan WeiXiaoqin ZhouMingna Sun
- Journals
- International Journal of Pharmaceutics (3 papers)Acta Pharmaceutica Sinica B (2 papers)International Journal of Biological Macromolecules (2 papers)
- Partner nations
- ChinaMacaoUnited States
In The Last Decade
Lingran Du
21 papers receiving 452 citations
Peers
Comparison fields: 5 of 82
- Pharmaceutical Science 73
- Biomaterials 109
- Cancer Research 63
- Molecular Medicine 19
- Biomedical Engineering 141
Countries citing papers authored by Lingran Du
This map shows the geographic impact of Lingran Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingran Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingran Du more than expected).
Fields of papers citing papers by Lingran Du
This network shows the impact of papers produced by Lingran Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingran Du. The network helps show where Lingran Du may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lingran Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 5 | |
| 7 | 2021 | 11 | |
| 8 | 2021 | 10 | |
| 9 | 2020 | 6 | |
| 10 | 2020 | 47 | |
| 11 | 2020 | 13 | |
| 12 | 2019 | 62 | |
| 13 | 2019 | 25 | |
| 14 | 2018 | 38 | |
| 15 | 2017 | 88 | |
| 16 | 2015 | 49 | |
| 17 | 2014 | 41 | |
| 18 | 2014 | 15 | |
| 19 | 2013 | 8 | |
| 20 | 2007 | 27 |
About Lingran Du
Lingran Du is a scholar working on Pharmaceutical Science, Biomaterials and Internal Medicine, having authored 22 papers that have together received 457 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (4 papers), RNA Interference and Gene Delivery (3 papers), Advanced biosensing and bioanalysis techniques (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Advancements in Transdermal Drug Delivery (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Intracranial Aneurysms: Treatment and Complications (2 papers) and Advanced Drug Delivery Systems (2 papers). The work is most often cited by research in Pharmaceutical Science (73 citations), Biomaterials (109 citations) and Cancer Research (63 citations). Lingran Du has collaborated with scholars based in China, Macao and United States. Frequent co-authors include Jijun Fu, Yi Zhou, Xiyong Yu, Yugang Huang, He Wang, Minyan Wei, Xiaoqin Zhou, Mingna Sun, Liang Gu and Jiayi Guo. Their work appears in journals such as International Journal of Pharmaceutics, Acta Pharmaceutica Sinica B, International Journal of Biological Macromolecules, Journal of Nanobiotechnology and Journal of Pharmacy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.